SLU-PP-332 (5 mg Vial) Dosage Protocol
Reconstitution and handling guide for the 5 mg SLU-PP-332 vial — an ERR (estrogen-related receptor) agonist studied as an 'exercise mimetic.' Note: human dosing is not established; preclinical research only.
Quickstart Highlights
SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptors (ERRα/β/γ), studied as an 'exercise mimetic' for increasing mitochondrial biogenesis, oxidative metabolism, endurance, and fat oxidation in preclinical (rodent) models. Important: its safety and effective dose in humans have not been established — all dosing below is approximate and circulated for research handling only.
- Composition: 5 mg SLU-PP-332 per vial
- Reconstitute: Add 2.0 mL bacteriostatic water → 2.5 mg/mL concentration
- Easy measuring: At 2.5 mg/mL, 1 unit (0.01 mL) on a U-100 syringe = 25 mcg
- Storage: Lyophilized: −20 °C (−4 °F); reconstituted: 2–8 °C (35.6–46.4 °F), protected from light, use within 2–4 weeks
Dosing & Reconstitution Guide
Subcutaneous handling protocol — preclinical compound, no validated human dose
Subcutaneous Protocol (5 mg vial, 2 mL = 2.5 mg/mL)
| Protocol | Per-dose (approx.) | Frequency | Units (U-100) |
|---|---|---|---|
| Low | 250 mcg | once daily | 10 units (0.10 mL) |
| Standard (circulated) | 500 mcg | once daily | 20 units (0.20 mL) |
Administration: SLU-PP-332 has only been characterized in preclinical research; there is no validated human dose. The figures above reflect amounts circulated in the research community and should be treated as experimental. Begin conservatively, if at all, within a research context.
Reconstitution Steps
- Allow the vial to reach room temperature (15–20 minutes out of cold storage).
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall to avoid foaming.
- Gently swirl or roll until fully dissolved (do not shake).
- Label with date and concentration; refrigerate at 2–8 °C, protected from light.
Result: 2.5 mg/mL concentration
How This Works
SLU-PP-332 activates the estrogen-related receptors (ERRs), master regulators of mitochondrial biogenesis and oxidative metabolism. In animal studies this shifts metabolism toward fat oxidation and increases endurance capacity without the animal exercising — hence the “exercise mimetic” label.
Because these effects are documented in rodents and the compound is early-stage, human efficacy, dosing, and safety remain unknown.
Key Administration Notes
- Preclinical compound — no established human dose or safety profile.
- If handled in research, start at the lowest amounts and document carefully.
- Use new sterile syringes; rotate sites; sharps disposal.
- Not for human consumption; research use only.
References
Billon C, et al. The ERR agonist SLU-PP-332 increases oxidative metabolism and endurance (exercise mimetic). View Source
Xu W, et al. Pharmacological activation of estrogen-related receptors with SLU-PP-332. View Source
⚠️ Research & Educational Purposes Only
This information is provided for research and educational purposes only. The compounds discussed are intended for laboratory research use only and are not approved for human consumption. Always consult qualified healthcare professionals for medical advice. Individual results may vary. This is not medical advice.